Insiders · INAB

Corinne Epperly

Director at In8bio, Inc. (INAB) since December 2023

Corinne Epperly has filed 12 insider reports with the SEC since April 2021, as director at In8bio, Inc. (INAB) and director at Aveo Pharmaceuticals, Inc. (AVEO). The latest filing, on May 12, 2026, reports grant or award at In8bio, Inc. (INAB).

Filings
12
Companies
2
Bought on market
None
Sold on market
None

Companies where Corinne Epperly is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
In8bio, Inc. logo
INAB
In8bio, Inc.
Directorsince December 202381,967$0.82May 12, 2026
Aveo Pharmaceuticals, Inc. logo
AVEO
Aveo Pharmaceuticals, Inc.
DirectorJan 19, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Corinne Epperly with

Other insiders at the same companies

Questions about Corinne Epperly

What is Corinne Epperly's role at In8bio, Inc.?
Corinne Epperly reports to the SEC as director at In8bio, Inc. (INAB), according to the latest filing on May 12, 2026. Corinne Epperly has also filed as director at Aveo Pharmaceuticals, Inc. (AVEO).
How many shares does Corinne Epperly own?
After the latest filing that states it, Corinne Epperly directly owned 81,967 shares of In8bio, Inc. (INAB). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Corinne Epperly bought or sold stock recently?
No open-market purchases or sales by Corinne Epperly are on file. The filings report grant or award and sale back to the company.
How do I get alerts when Corinne Epperly files?
Follow Corinne Epperly on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Corinne Epperly (SEC CIK 0001839156). Totals count each trade once, skipping amendments whose original is on file, from Apr 14, 2021 on. View on SEC EDGAR